Answers are grounded in this paper and cite their sources.
Background The role and optimal sequencing of systemic therapy in patients with high-volume peritoneal mesothelioma (PeM) undergoing curative-intent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) remains unclear. We compared perioperative outcomes in patients undergoing upfront CRS/HIPEC (U-CRS) versus those receiving neoadjuvant therapy (NAT). Methods This single-institution retrospective study included patients with PeM (2009-2023) who underwent CRS/HIPEC with a peritoneal carcinomatosis index (PCI) >20. Primary outcomes were prolonged operative time (OT), defined as >75 th percentile for the study cohort, and 90-day postoperative complications. Secondary outcomes included complete cytoreduction with CC-0 score, recurrence-free survival (RFS), and overall survival (OS). Results Of 45 patients, 14 (31%) underwent U-CRS and 31 (69%) received NAT. Most NAT patients (94%) were treated with a platinum agent and pemetrexed, with or without bevacizumab, for a median of 6 cycles. Median PCI was similar between groups (U-CRS: 28; NAT: 27; p =0.73). Median OT was 572minutes (U-CRS) vs. 645minutes (NAT; p =0.17). Grade III–V complications occurred in 50% of U-CRS vs. 32% of NAT patients ( p =0.42). NAT was not independently associated with prolonged OT or severe complications on multivariable analyses. Rates of CC-0 resection, RFS, and OS were similar between groups. Conclusions NAT is feasible and safe in patients with high-volume PeM undergoing CRS/HIPEC, without negatively affecting perioperative outcomes. The neoadjuvant setting offers a valuable platform for investigating novel therapies aimed at improving long-term outcomes in PeM. SYNOPSIS Neoadjuvant systemic therapy before CRS/HIPEC for high-volume peritoneal mesothelioma is feasible and safe with similar operative times and complication rates as upfront surgery, supporting its use as a platform to evaluate novel therapies to improve long-term outcomes in peritoneal mesothelioma.
No takes yet. Share an insight, caveat, or question.
Song et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: